Live
FierceBiotechGHO Capital, CBC Group plan to merge, forming $21B healthcare investment firmClinical OMICsEarly Medical Care Linked to Rapid Gut Microbiome Shifts in Amazonian Indigenous CommunitiesClinical OMICsAI Shows Value for Breast Cancer PredictionFierceBiotechQiagen links with chip giant Nvidia to propel AI use in drug discoveryClinical OMICsMolecular Imaging Could Detect Early Kidney FibrosisClinical OMICsUltra-Short Radiotherapy Schedule for Prostate Cancer Supported by HERMES TrialEndpoints NewsI&I biotech cAMPfield attracts top-tier investors in $180M Series AClinical OMICsMYC Protein Linked to Tumor Survival Through DNA Repair PathwayEndpoints NewsThe next big pharma company will come from ChinaClinical OMICsctDNA and Immune Signals Reveal Who Benefits Most from Metastasis-Directed RadiationEndpoints NewsDriven by GLP-1s, pharma’s relationship with consumers is starting to changeClinical OMICsImpact of Current Genetic Testing on Cancer Survivor Treatment
FierceBiotech Apr 2, 2026

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest

Immunovant’s FcRn inhibitor flunks phase 3 eye disease trials, validating biotech’s waning interest

Original
Body unavailable. Use the original source.